P3 Health Partners Provides Third-Quarter and Year-to-Date 2022 Financial Results
P3 Health Partners reported a 59% revenue growth in Q3 2022, totaling $248.3 million, up from $156.2 million in Q3 2021. However, net loss increased to $65.3 million, compared to $32.1 million a year prior, primarily due to a $851.5 million goodwill impairment charge. Year-to-date revenue stands at $791.3 million, a 75% increase year-over-year. Adjusted EBITDA loss for the first nine months was $87.9 million, worse than the prior year's $59.9 million. Guidance for full-year Adjusted EBITDA loss has been revised to $118-$128 million.
- Year-to-date revenue growth of 75% to $791.3 million.
- Q3 revenue of $248.3 million, increasing 59% year-over-year.
- At-risk Medicare Advantage membership increased to approximately 101,000, up 67%.
- Net loss increased significantly to $1.0 billion year-to-date, primarily due to goodwill impairment.
- Adjusted EBITDA loss worsened to $87.9 million, compared to $59.9 million last year.
- Full-year 2022 Adjusted EBITDA loss guidance revised upward to $118-$128 million, indicating a substantial increase in expected losses.
-
Strong Third-Quarter YTD 2022 revenue growth of
59% compared to the Third-Quarter YTD 2021 - At-risk Medicare Advantage members exceeded 101,000 at the end of the Third Quarter of 2022
-
Third-Quarter YTD 2022 Net loss PMPM increased to
from$1,132 for Third-quarter YTD 2021, primarily due to an$159 goodwill impairment charge recorded in the Second Quarter of 2022$851.5 million -
Adjusted EBITDA loss PMPM improved in first nine months of 2022 at a PMPM loss of
compared to a PMPM loss of$97 in the first nine months of 2021$110 - Providing Updated Full-Year 2023 Adjusted EBITDA guidance
-
Management to Host Conference Call and Webcast
November 14, 2022 , at4:30 PM ET
“We are pleased to report another strong quarter of growth, with
Third-Quarter 2022 Financial Results
-
Revenue was
, an increase of$248.3 million 59% compared to in the third quarter of the prior year$156.2 million -
At-risk Medicare Advantage members at
September 30, 2022 were approximately 101,000, a67% increase compared to 60,300 at the end of the third quarter of the prior year(1) -
Net loss was
compared to a net loss of$65.3 million in the third quarter of the prior year$32.1 million -
Net loss per member per month (PMPM) increased to
from a loss of$216 in the third quarter of the prior year$177 -
Adjusted EBITDA(2) loss was
compared to an adjusted EBITDA loss of$40.3 million in the third quarter of the prior year$25.7 million -
Adjusted EBITDA(2) loss PMPM was
, an improvement from a loss of$133 in the third quarter of the prior year$142
Third-Quarter Year-to-Date 2022 Financial Results
-
Revenue was
, an increase of$791.3 million 75% compared to in the first nine months of the prior year$452.1 million -
Net loss was
compared to a net loss of$1.0 billion in the first nine months of the prior year, primarily due to an$86.2 million goodwill impairment charge$851.5 -
Net loss PMPM was
compared to a net loss of$1,132 in the first nine months of the prior year, primarily due to a goodwill impairment of$159 $851.5 million -
Adjusted EBITDA(2) loss was
compared to an adjusted EBITDA loss of$87.9 million in the first nine months of the prior year(1) as a result of increased members in our care$59.9 million -
Adjusted EBITDA(2) loss PMPM improved to
from$97 compared to the first nine months of the prior year$110
(1) See “Key Performance Metrics” for additional information on how the Company defines “at-risk Medicare Advantage members.”
(2) Adjusted EBITDA and Adjusted EBITDA PMPM are non-GAAP financial measures. For reconciliations of these measures to the most directly comparable GAAP measures and more information regarding the Company’s use of non-GAAP financial measures, please see the section titled “Non-GAAP Financial Measures.”
Full-Year 2022 Outlook
-
The Company still expects full-year 2022 revenue between
and$1.02 5 billion , representing a$1.07 5 billion61% to69% increase over the prior year and at-risk Medicare Advantage membership to be greater than 100,000, atDecember 31, 2022 -
The Company now expects full-year 2022 Adjusted EBITDA(2) loss to range between
and$118 million , a change from the prior guidance range of between$128 million and$55 million , primarily due to the return to normal timing of cash sweep recognition, consistent with our existing revenue recognition policy, following the extended 2021 audit, which resulted in approximately$90 million to$15 in sweeps that will be recognized in 2023 instead of 2022. The change also reflects$20 million in profits moved to 2021 due to the length of its 2021 audit and non-recurring costs in the range of$12 million to$7 million associated with the audit$10 million -
On a PMPM basis, full-year 2022 Adjusted EBITDA(2) loss is now expected to fall in the range of
PMPM to$97 PMPM, primarily due to the return to normal timing of cash sweep recognition, consistent with our existing revenue recognition policy, following the extended 2021 audit, which results in approximately$107 to$15 in sweeps that will be recognized in 2023 instead of 2022. The change also reflects$20 million in profits moved to 2021 due to the length of its 2021 audit and non-recurring costs in the range of$12 million to$7 million associated with the audit. The new range reflects an improvement of$10 million 11% -22% compared to a loss of PMPM in the prior year$119 - The company still anticipates Adjusted EBITDA profitability in 2024
While the Company expects COVID-19 to impact our future results to a lesser extent than our full-year 2021 results, P3 expects to incur additional COVID-19 related costs in full year 2022 given the volume of positive cases and “breakthrough” cases (positive cases in vaccinated patients) present in the Company’s markets. COVID-19 disproportionately impacts older adults, especially those with chronic illnesses, which describes many of P3’s patients. The full extent to which COVID-19 will directly or indirectly impact P3’s full year 2022 results of operations and financial condition will depend on multiple factors, including, but not limited to new and emerging information from the impact of new variants of the virus. Because of these factors, management may not be able to fully estimate the length or severity of the impact of the pandemic on P3’s business and results of operations.
The foregoing 2022 outlook statement represents management's current estimate as of the date of this release. Actual results may differ materially depending on a number of factors. Investors are urged to read the Cautionary Note Regarding Forward-Looking Statements included in this release. Management does not assume any obligation to update these estimates.
The Company is not able to provide a quantitative reconciliation of guidance for Adjusted EBITDA loss or Adjusted EBITDA loss PMPM to net income (loss) and net income (loss) PMPM, the most directly comparable GAAP measures, respectively, and has not provided forward-looking guidance for net income (loss) or net income (loss) PMPM, because of the uncertainty around certain items that may impact net income (loss) that are not within our control or cannot be reasonably predicted without unreasonable effort. For more information regarding the non-GAAP financial measures discussed in this press release, please see “Non-GAAP Financial Measures” below.
Restatement of the Company's Historical Financial Statements
As disclosed in the Current Report on Form 8-K filed with the
Conference Call and Webcast
Management will host a conference call and webcast at
Title & Webcast |
P3 Health Partners Third-Quarter 2022 Results Conference Call and Webcast |
Date & Time |
|
Conference Call Details |
Toll-Free 1-877-407-4018 (US) International 1-201-689-8471 Conference ID: 13734101 |
The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the P3 website (ir.p3hp.org). The Company’s press release will be available on the Investor page of P3’s website in advance of the conference call. An archived recording of the webcast will be available on the Investor page of P3’s website for a period of 90 days following the conference call. |
About
Business Combination and Presentation of Financial Results
As a result of the business combination consummated on
Non-GAAP Financial Measures
In addition to the financial results prepared in accordance with
Key Performance Metrics
In addition to our GAAP and non-GAAP financial information, the Company also monitors “at-risk members” to help us evaluate our business, identify trends affecting our business, formulate business plans and make strategic decisions. At-risk membership represents the approximate number of Medicare Advantage members for whom we receive a fixed per member per month fee under capitation arrangements as of the end of a particular period.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipate," "believe," "budget," "contemplate," "continue," "could," "envision," "estimate," "expect," "guidance," "indicate," "intend," "may," "might," "plan," "possibly," "potential," "predict," "probably," "pro-forma," "project," "seek," "should," "target," or "will," or the negative or other variations thereof, and similar words or phrases or comparable terminology, are intended to identify forward-looking statements. These forward-looking statements address various matters, including the Company’s future expected growth strategy and operating performance; current expectations regarding the COVID-19 pandemic; the Company’s outlook as to revenue, at-risk Medicare Advantage membership, Adjusted EBITDA loss and Adjusted EBITDA loss PMPM for the full-year 2022; and our expectation to achieve Adjusted EBITDA profitability in 2024, all of which reflect the Company’s expectations based upon currently available information and data. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected or estimated and you are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements.
Important risks and uncertainties that could cause our actual results and financial condition to differ materially from those indicated in forward-looking statements include, among others, changes in market or industry conditions, regulatory environment, competitive conditions, and receptivity to our services; our ability to continue our growth and expand our operations; changes in laws and regulations applicable to our business; our ability to maintain our relationships with health plans and other key payers; the impact of COVID-19, including the impact of new variants of the virus, or another pandemic, epidemic or outbreak of infectious disease on our business and results of operation; increased labor costs; our ability to recruit and retain qualified team members and independent physicians; and other factors discussed in Part I, Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended
|
||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
||||||||
(UNAUDITED) |
||||||||
|
|
As of |
|
As of |
||||
ASSETS |
|
|
|
|
|
|
||
CURRENT ASSETS: |
|
|
|
|
|
|
||
Cash |
|
$ |
34,357,237 |
|
|
$ |
140,477,586 |
|
Restricted Cash |
|
|
1,003,307 |
|
|
|
356,286 |
|
Health Plan Receivables, Net |
|
|
81,497,703 |
|
|
|
50,251,004 |
|
Clinic Fees and Insurance Receivables, Net |
|
|
1,049,253 |
|
|
|
1,090,104 |
|
Other Receivables |
|
|
2,736,184 |
|
|
|
726,903 |
|
Prepaid Expenses and Other Current Assets |
|
|
3,523,867 |
|
|
|
6,959,067 |
|
TOTAL CURRENT ASSETS |
|
|
124,167,551 |
|
|
|
199,860,950 |
|
LONG-TERM ASSETS: |
|
|
|
|
|
|
||
Property and Equipment |
|
|
11,509,656 |
|
|
|
8,230,250 |
|
Less: Accumulated Depreciation |
|
|
(1,994,380 |
) |
|
|
(182,321 |
) |
Property and Equipment, Net |
|
|
9,515,276 |
|
|
|
8,047,929 |
|
|
|
|
463,496,191 |
|
|
|
1,309,750,216 |
|
Intangible Assets, Net |
|
|
772,411,083 |
|
|
|
835,838,605 |
|
Notes Receivable, Net |
|
|
3,563,462 |
|
|
|
3,590,715 |
|
Right of Use Asset |
|
|
9,977,886 |
|
|
|
7,020,045 |
|
TOTAL LONG-TERM ASSETS |
|
|
1,258,963,898 |
|
|
|
2,164,247,510 |
|
TOTAL ASSETS (1) |
|
$ |
1,383,131,449 |
|
|
$ |
2,364,108,460 |
|
LIABILITIES, MEZZANINE EQUITY and STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
||
CURRENT LIABILITIES: |
|
|
|
|
|
|
||
Accounts Payable and Accrued Expenses |
|
$ |
24,072,391 |
|
|
$ |
17,730,683 |
|
Accrued Payroll |
|
|
7,358,102 |
|
|
|
6,304,362 |
|
Health Plans Settlements Payable |
|
|
20,626,836 |
|
|
|
22,548,694 |
|
Claims Payable |
|
|
134,705,426 |
|
|
|
101,958,324 |
|
Premium Deficiency Reserve |
|
|
27,719,928 |
|
|
|
37,835,642 |
|
Accrued Interest |
|
|
12,655,918 |
|
|
|
8,771,065 |
|
Current Portion of Long-Term Debt |
|
|
— |
|
|
|
46,101 |
|
Short-Term Debt |
|
|
— |
|
|
|
3,578,561 |
|
TOTAL CURRENT LIABILITIES |
|
|
227,138,601 |
|
|
|
198,773,432 |
|
LONG-TERM LIABILITIES: |
|
|
|
|
|
|
||
Right of Use Liability |
|
|
11,156,949 |
|
|
|
6,296,883 |
|
Warrant Liabilities |
|
|
7,996,432 |
|
|
|
11,382,826 |
|
Contingent Consideration |
|
|
4,684,503 |
|
|
|
3,486,593 |
|
Long-Term Debt |
|
|
80,000,000 |
|
|
|
80,000,000 |
|
TOTAL LONG-TERM LIABILITIES |
|
|
103,837,884 |
|
|
|
101,166,302 |
|
TOTAL LIABILITIES (1) |
|
|
330,976,485 |
|
|
|
299,939,734 |
|
COMMITMENTS AND CONTINGENCIES (NOTE 23) |
|
|
|
|
|
|
||
MEZZANINE EQUITY |
|
|
|
|
|
|
||
Redeemable Non-Controlling Interest |
|
|
974,078,949 |
|
|
|
1,790,617,285 |
|
STOCKHOLDERS’ EQUITY: |
|
|
|
|
|
|
||
Class A Common Stock, |
|
|
4,158 |
|
|
|
4,158 |
|
Class V Common Stock, |
|
|
20,153 |
|
|
|
19,655 |
|
Additional Paid in Capital |
|
|
293,570,464 |
|
|
|
312,945,752 |
|
Accumulated Deficit |
|
|
(215,518,760 |
) |
|
|
(39,418,124 |
) |
TOTAL STOCKHOLDERS’ EQUITY |
|
|
78,076,015 |
|
|
|
273,551,441 |
|
TOTAL LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS’ EQUITY |
|
$ |
1,383,131,449 |
|
|
$ |
2,364,108,460 |
|
(1) |
The Company’s condensed consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities (“VIEs”). As discussed in Note 25 “Variable Interest Entities,” |
|
||||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
||||||||||||||||||
(UNAUDITED) |
||||||||||||||||||
|
|
Successor |
|
|
Predecessor |
|
Successor |
|
|
Predecessor |
||||||||
|
|
Three Months Ended |
|
|
Three Months Ended |
|
Nine Months Ended |
|
|
Nine Months Ended |
||||||||
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
|
|
|
|
(As Restated) |
|
|
|
|
|
(As Restated) |
||||||
OPERATING REVENUE: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Capitated Revenue |
|
$ |
243,988,004 |
|
|
|
$ |
153,072,995 |
|
|
$ |
780,775,285 |
|
|
|
$ |
443,598,050 |
|
Other Patient Service Revenue |
|
|
4,272,069 |
|
|
|
|
3,112,960 |
|
|
|
10,483,093 |
|
|
|
|
8,472,288 |
|
TOTAL OPERATING REVENUE |
|
|
248,260,073 |
|
|
|
|
156,185,955 |
|
|
|
791,258,378 |
|
|
|
|
452,070,338 |
|
OPERATING EXPENSES: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Medical Expenses |
|
|
254,776,548 |
|
|
|
|
161,328,123 |
|
|
|
788,045,718 |
|
|
|
|
458,333,145 |
|
Premium Deficiency Reserve |
|
|
(7,301,630 |
) |
|
|
|
1,600,000 |
|
|
|
(10,115,714 |
) |
|
|
|
4,600,000 |
|
Corporate, General and Administrative Expenses |
|
|
37,862,737 |
|
|
|
|
20,433,538 |
|
|
|
117,560,549 |
|
|
|
|
53,883,267 |
|
Sales and Marketing Expenses |
|
|
1,119,552 |
|
|
|
|
491,418 |
|
|
|
3,392,178 |
|
|
|
|
1,118,160 |
|
Goodwill Impairment |
|
|
— |
|
|
|
|
— |
|
|
|
851,455,754 |
|
|
|
|
— |
|
Depreciation and Amortization |
|
|
21,814,803 |
|
|
|
|
456,418 |
|
|
|
65,286,715 |
|
|
|
|
1,218,797 |
|
TOTAL OPERATING EXPENSES |
|
|
308,272,010 |
|
|
|
|
184,309,497 |
|
|
|
1,815,625,200 |
|
|
|
|
519,153,369 |
|
OPERATING LOSS |
|
|
(60,011,937 |
) |
|
|
|
(28,123,542 |
) |
|
|
(1,024,366,822 |
) |
|
|
|
(67,083,031 |
) |
OTHER INCOME (EXPENSES): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest Expense, net |
|
|
(2,749,681 |
) |
|
|
|
(2,529,133 |
) |
|
|
(8,244,806 |
) |
|
|
|
(7,023,187 |
) |
Mark-to-Market of Stock Warrants |
|
|
(2,567,423 |
) |
|
|
|
(1,401,686 |
) |
|
|
3,386,394 |
|
|
|
|
(12,063,265 |
) |
TOTAL OTHER INCOME (EXPENSE) |
|
|
(5,317,104 |
) |
|
|
|
(3,930,819 |
) |
|
|
(4,858,412 |
) |
|
|
|
(19,086,452 |
) |
LOSS BEFORE INCOME TAXES |
|
|
(65,329,041 |
) |
|
|
|
(32,054,361 |
) |
|
|
(1,029,225,234 |
) |
|
|
|
(86,169,483 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
PROVISION FOR INCOME TAXES |
|
|
— |
|
|
|
|
— |
|
|
|
— |
|
|
|
|
— |
|
NET LOSS |
|
|
(65,329,041 |
) |
|
|
|
(32,054,361 |
) |
|
|
(1,029,225,234 |
) |
|
|
|
(86,169,483 |
) |
LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS |
|
|
(54,155,858 |
) |
|
|
|
— |
|
|
|
(853,124,598 |
) |
|
|
|
— |
|
NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS |
|
$ |
(11,173,183 |
) |
|
|
$ |
(32,054,361 |
) |
|
$ |
(176,100,636 |
) |
|
|
$ |
(86,169,483 |
) |
NET LOSS PER SHARE (BASIC) |
|
$ |
(0.27 |
) |
|
|
|
N/A1 |
|
$ |
(4.24 |
) |
|
|
|
N/A1 |
||
NET LOSS PER SHARE (DILUTED) |
|
$ |
(0.27 |
) |
|
|
|
N/A1 |
|
$ |
(4.27 |
) |
|
|
|
N/A1 |
||
See accompanying notes to condensed consolidated financial statements. |
_______________________ |
1 The Company analyzed the calculation of net loss per member unit for predecessor periods prior to the Business Combinations and determined that it resulted in values that would not be meaningful to the users of these consolidated financial statements. Therefore, net loss per member unit information has not been presented for predecessor periods prior to the Business Combinations on |
|
|||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||||
(UNAUDITED) |
|||||||||
|
|
Successor |
|
|
Predecessor |
||||
|
|
Nine Months Ended |
|
|
Nine Months Ended |
||||
|
|
|
|
|
|
||||
|
|
|
|
|
(As Restated) |
||||
Cash Flows from Operating Activities |
|
|
|
|
|
|
|
||
Net Loss |
|
$ |
(1,029,225,234 |
) |
|
|
$ |
(86,169,483 |
) |
Adjustments to Reconcile Net Loss to |
|
|
|
|
|
|
|
||
Depreciation and Amortization |
|
|
65,286,715 |
|
|
|
|
1,218,796 |
|
Stock-Based Compensation |
|
|
17,210,974 |
|
|
|
|
1,379,400 |
|
Goodwill Impairment |
|
|
851,455,754 |
|
|
|
|
— |
|
Amortization of Debt Origination Fees |
|
|
— |
|
|
|
|
525,783 |
|
Amortization of Discount from Issuance of Debt |
|
|
— |
|
|
|
|
931,958 |
|
Mark-to-Market Adjustment of Stock Warrants |
|
|
(3,386,394 |
) |
|
|
|
12,063,265 |
|
Premium Deficiency Reserve |
|
|
(10,115,714 |
) |
|
|
|
4,600,000 |
|
Non-cash Interest Expense |
|
|
290,910 |
|
|
|
|
— |
|
Changes in Assets and Liabilities: |
|
|
|
|
|
|
|
||
Accounts Receivable |
|
|
(1,623,188 |
) |
|
|
|
54,602 |
|
Health Plan Receivables / Premiums |
|
|
(31,246,699 |
) |
|
|
|
(884,523 |
) |
Other Current Assets |
|
|
3,462,453 |
|
|
|
|
2,667,427 |
|
Net Change in ROU Assets and Liabilities |
|
|
3,500,981 |
|
|
|
|
379,235 |
|
Accounts Payable |
|
|
4,560,474 |
|
|
|
|
3,606,729 |
|
Accrued Payroll |
|
|
1,053,740 |
|
|
|
|
(1,842,877 |
) |
Accrued Interest |
|
|
3,884,853 |
|
|
|
|
3,952,044 |
|
Health Plan Payables / Premiums |
|
|
(1,921,858 |
) |
|
|
|
(483,657 |
) |
Claims Payable |
|
|
32,747,102 |
|
|
|
|
18,173,851 |
|
|
|
|
(94,065,131 |
) |
|
|
|
(39,827,450 |
) |
Cash Flows from Investing activities |
|
|
|
|
|
|
|
||
Purchase of Property, Plant and Equipment |
|
|
(2,283,404 |
) |
|
|
|
(2,990,130 |
) |
Acquisitions |
|
|
(5,500,131 |
) |
|
|
|
(5,014,500 |
) |
Increase in Notes Receivable, Net |
|
|
— |
|
|
|
|
120,463 |
|
|
|
|
(7,783,535 |
) |
|
|
|
(7,884,167 |
) |
Cash Flows from Financing activities |
|
|
|
|
|
|
|
||
Issuance of Long-Term Debt |
|
|
— |
|
|
|
|
12,750,000 |
|
Repayment of Short-Term and Long-Term Debt |
|
|
(3,624,662 |
) |
|
|
|
(67,216 |
) |
Loan Origination and Closing Fees |
|
|
— |
|
|
|
|
(191,250 |
) |
|
|
|
(3,624,662 |
) |
|
|
|
12,491,534 |
|
Net Change in Cash and Restricted Cash |
|
|
(105,473,328 |
) |
|
|
|
(35,220,083 |
) |
Cash and Restricted Cash, Beginning of Period |
|
|
140,833,872 |
|
|
|
|
39,902,947 |
|
Cash and Restricted Cash, End of Period |
|
$ |
35,360,544 |
|
|
|
$ |
4,682,864 |
|
See accompanying notes to condensed consolidated financial statements. |
Reconciliation of Non-GAAP Adjusted EBITDA | ||||||||
(in millions) | ||||||||
Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | |||||
Net Loss |
( |
) |
( |
) |
( |
) |
( |
) |
Interest Expense, Net | 2.8 |
|
2.5 |
|
8.2 |
|
7.0 |
|
Depreciation and Amortization Expense | 21.8 |
|
0.5 |
|
65.3 |
|
1.2 |
|
Goodwill Impairment | - |
|
0.0 |
|
851.5 |
|
- |
|
Mark-To-Market Adjustment For Stock Warrants | 2.6 |
|
1.4 |
|
(3.4 |
) |
12.1 |
|
Premium Deficiency Reserve | (7.3 |
) |
1.6 |
|
(10.1 |
) |
4.6 |
|
Transaction Expense, Business Combinations | 0.1 |
|
- |
|
2.2 |
|
- |
|
Transaction Related Litigation Expense | 0.3 |
|
- |
|
1.4 |
|
- |
|
Transaction Bonuses | 1.4 |
|
- |
|
7.3 |
|
- |
|
Stock-Based Compensation | 1.8 |
|
0.4 |
|
17.2 |
|
1.4 |
|
Restatement related cost | 1.6 |
|
- |
|
1.6 |
|
- |
|
Other | - |
|
- |
|
0.1 |
|
- |
|
EBITDA, Adjusted |
( |
) |
( |
) |
( |
) |
( |
) |
Reconciliation of non-GAAP adjusted EBITDA / PMPM | ||||||||
(in PMPM $) | ||||||||
Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | |||||
Net Loss |
( |
) |
( |
) |
( |
) |
( |
) |
Interest Expense, Net |
|
|
|
|
|
|
|
|
Depreciation and Amortization Expense |
|
|
|
|
|
|
|
|
Goodwill Impairment |
|
|
|
|
|
|
|
|
Mark-To-Market Adjustment For Stock Warrants |
|
|
|
|
( |
) |
|
|
Premium Deficiency Reserve |
( |
) |
|
|
( |
) |
|
|
Transaction Expense, Business Combinations |
|
|
|
|
|
|
|
|
Transaction Related Litigation Expense |
|
|
|
|
|
|
|
|
Transaction Bonuses |
|
|
|
|
|
|
|
|
Stock-Based Compensation |
|
|
|
|
|
|
|
|
Restatement related cost |
|
|
|
|
|
|
|
|
Other |
|
|
|
|
|
|
|
|
EBITDA, Adjusted |
( |
) |
( |
) |
( |
) |
( |
) |
Reconciliation of Non-GAAP Adjusted EBITDA | ||
(in millions) | ||
For the Year Ended | ||
Net Loss |
( |
) |
Interest Expense, Net |
|
|
Depreciation and Amortization Expense |
|
|
Goodwill Impairment |
|
|
Mark-To-Market Adjustment For Stock Warrants |
|
|
Premium Deficiency Reserve |
|
|
Transaction Expense, Business Combinations |
|
|
Transaction Related Litigation Expense |
|
|
Transaction Bonuses | ||
Stock-Based Compensation |
|
|
Restatement related cost |
|
|
Other |
|
|
EBITDA, Adjusted |
( |
) |
Reconciliation of non-GAAP adjusted EBITDA / PMPM | ||
(in PMPM $) | ||
For the Year Ended | ||
Net Loss |
( |
) |
Interest Expense, Net |
|
|
Depreciation and Amortization Expense |
|
|
Goodwill Impairment |
|
|
Mark-To-Market Adjustment For Stock Warrants |
|
|
Premium Deficiency Reserve |
|
|
Transaction Expense, Business Combinations |
|
|
Transaction Related Litigation Expense |
|
|
Transaction Bonuses |
|
|
Stock-Based Compensation |
|
|
Restatement related cost |
|
|
Other |
|
|
EBITDA, Adjusted |
( |
) |
View source version on businesswire.com: https://www.businesswire.com/news/home/20221114005444/en/
Investor Relations
Vice President, Investor Relations
kblomquist@p3hp.org
Managing Director
shalper@lifesciadvisors.com
Executive Vice President, Communications
(904) 415-2744
kbelz@p3hp.org
Source:
FAQ
What were P3 Health Partners' Q3 earnings results for 2022?
What is the net loss reported by P3 Health Partners for Q3 2022?
What is P3 Health Partners' updated guidance for full-year 2022 Adjusted EBITDA?
How many Medicare Advantage members does P3 Health Partners have as of Q3 2022?